EMERGENT BIOSOLUTIONS INC. Depreciation
EMERGENT BIOSOLUTIONS INC. (EBS) reported Depreciation of $6.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-06
- EMERGENT BIOSOLUTIONS INC. depreciation for the quarter ending 2026-06-30 was $6.80M, a 6.85% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. depreciation for the quarter ending 2026-03-31 was $7.00M, a 23.08% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. depreciation for the quarter ending 2025-12-31 was $7.20M, a 25.77% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. depreciation for the quarter ending 2025-09-30 was $7.10M, a 29.70% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. depreciation for fiscal 2025 was $30.70M, a 29.75% decline from fiscal 2024.
- EMERGENT BIOSOLUTIONS INC. depreciation for fiscal 2024 was $43.70M, a 26.55% decline from fiscal 2023.
- EMERGENT BIOSOLUTIONS INC. depreciation for fiscal 2023 was $59.50M, a 28.66% decline from fiscal 2022.
- EMERGENT BIOSOLUTIONS INC. depreciation for fiscal 2022 was $83.40M, a 34.08% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 3 month as first filed | Depreciation 6 month | Depreciation 9 month | Depreciation 9 month as first filed | Depreciation 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6.80M 10-Q · filed 2026-08-06 | $13.80M 10-Q · filed 2026-08-06 | $21.00M derived: sum of 3 quarters · filed 2026-08-06 | $28.10M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $7.00M 10-Q · filed 2026-05-01 | $14.20M derived: sum of 2 quarters · filed 2026-05-01 | $21.30M derived: sum of 3 quarters · filed 2026-05-01 | $28.60M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $7.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $14.30M derived: sum of 2 quarters · filed 2026-02-27 | $21.60M derived: sum of 3 quarters · filed 2026-08-06 | $30.70M 10-K · filed 2026-02-27 | ||
| 2025-09-30 | $7.10M 10-Q · filed 2025-10-30 | $14.40M derived: sum of 2 quarters · filed 2026-08-06 | $23.50M 10-Q · filed 2025-10-30 | $33.20M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $7.30M 10-Q · filed 2026-08-06 | $16.40M 10-Q · filed 2026-08-06 | $26.10M derived: sum of 3 quarters · filed 2026-08-06 | $36.20M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $9.10M 10-Q · filed 2026-05-01 | $18.80M derived: sum of 2 quarters · filed 2026-05-01 | $28.90M derived: sum of 3 quarters · filed 2026-05-01 | $41.10M derived: sum of 4 quarters · filed 2026-05-01 | ||
| 2024-12-31 | $9.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $19.80M derived: sum of 2 quarters · filed 2026-02-27 | $32.00M derived: sum of 3 quarters · filed 2026-02-27 | $43.70M 10-K · filed 2026-02-27 | ||
| 2024-09-30 | $10.10M 10-Q · filed 2025-10-30 | $22.30M derived: sum of 2 quarters · filed 2025-10-30 | $34.00M 10-Q · filed 2025-10-30 | $47.40M derived: sum of 4 quarters · filed 2026-02-27 | ||
| 2024-06-30 | $12.20M 10-Q · filed 2025-08-07 | $23.90M 10-Q · filed 2025-08-07 | $37.30M derived: sum of 3 quarters · filed 2026-02-27 | $49.00M derived: sum of 4 quarters · filed 2026-02-27 | ||
| 2024-03-31 | $11.70M 10-Q · filed 2025-05-08 | $25.10M derived: sum of 2 quarters · filed 2026-02-27 | $36.80M derived: sum of 3 quarters · filed 2026-02-27 | $53.60M derived: sum of 4 quarters · filed 2026-02-27 | ||
| 2023-12-31 | $13.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $25.10M derived: sum of 2 quarters · filed 2026-02-27 | $41.90M derived: sum of 3 quarters · filed 2026-02-27 | $59.50M 10-K · filed 2026-02-27 | ||
| 2023-09-30 | $11.70M 10-Q · filed 2024-11-07 | $28.50M derived: sum of 2 quarters · filed 2024-11-07 | $46.10M 10-Q · filed 2024-11-07 | $64.10M derived: sum of 4 quarters · filed 2025-03-04 | ||
| 2023-06-30 | $16.80M 10-Q · filed 2024-08-07 | $34.40M 10-Q · filed 2024-08-07 | $52.40M derived: sum of 3 quarters · filed 2025-03-04 | $72.70M derived: sum of 4 quarters · filed 2025-03-04 | ||
| 2023-03-31 | $17.60M 10-Q · filed 2024-05-02 | $35.60M derived: sum of 2 quarters · filed 2025-03-04 | $55.90M derived: sum of 3 quarters · filed 2025-03-04 | $84.40M derived: sum of 4 quarters · filed 2025-03-04 | ||
| 2022-12-31 | $18.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $38.30M derived: sum of 2 quarters · filed 2025-03-04 | $66.80M derived: sum of 3 quarters · filed 2025-03-04 | $83.40M 10-K · filed 2025-03-04 | ||
| 2022-09-30 | $20.30M 10-Q · filed 2023-12-11 | $20.40M 10-Q · filed 2022-11-09 | $48.80M derived: sum of 2 quarters · filed 2023-12-11 | $65.40M 10-Q · filed 2023-12-11 | $65.50M 10-Q · filed 2022-11-09 | $81.10M derived: sum of 4 quarters · filed 2024-03-08 |
| 2022-06-30 | $28.50M 10-Q · filed 2023-08-09 | $45.10M 10-Q · filed 2023-08-09 | $60.80M derived: sum of 3 quarters · filed 2024-03-08 | $75.20M derived: sum of 4 quarters · filed 2024-03-08 | ||
| 2022-03-31 | $16.60M 10-Q · filed 2023-05-10 | $32.30M derived: sum of 2 quarters · filed 2024-03-08 | $46.70M derived: sum of 3 quarters · filed 2024-03-08 | $65.20M derived: sum of 4 quarters · filed 2024-03-08 | ||
| 2021-12-31 | $15.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $30.10M derived: sum of 2 quarters · filed 2024-03-08 | $48.60M derived: sum of 3 quarters · filed 2024-03-08 | $62.20M 10-K · filed 2024-03-08 | ||
| 2021-09-30 | $14.40M 10-Q · filed 2022-11-09 | $32.90M derived: sum of 2 quarters · filed 2022-11-09 | $46.50M 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | $18.50M 10-Q · filed 2022-08-02 | $32.10M 10-Q · filed 2022-08-02 | ||||
| 2021-03-31 | $13.60M 10-Q · filed 2022-04-29 | |||||
| 2020-12-31 | $50.10M 10-K/A · filed 2023-12-11 | |||||
| 2019-12-31 | $49.50M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |